Clinical trial
Metabolic Effects of Switching Kaletra to Boosted Reyataz
NCT00413153 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00413153 |
|---|---|
| Title | Metabolic Effects of Switching Kaletra to Boosted Reyataz |
| Official title | Metabolic Effects of Switching Kaletra to Boosted Reyataz |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | atazanavir/ritonavir, lopinavir/ritonavir |
| Enrollment | 15 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Mar 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: